Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 shareholder update, highlighting plans to expand its oncology pipeline through the proposed acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics. CL-741 targets EGFR-mutated lung cancer and other cancers, complementing Kairos' existing portfolio, which includes ENV-105, KROS-201, KROS-102, and ENV-205. The company expects to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings, and pursue pharmaceutical collaborations.
Kairos Pharma also noted it has secured more than $8 million in non-dilutive funding to support the development of its preclinical and clinical programs. The update underscores the company's progress and strategic direction in oncology therapeutics. ENV-105, the company's lead candidate, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. It aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. ENV-105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs.
For more details, the full press release is available at https://ibn.fm/WuBOf. Kairos Pharma, based in Los Angeles, California, is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's pipeline includes multiple candidates targeting various cancer types. As of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. The latest news and updates relating to KAPA are available at https://ibn.fm/KAPA.
The update also highlights the company's commitment to advancing its clinical programs and expanding its pipeline through strategic acquisitions. The addition of CL-741 could provide a new treatment option for patients with EGFR-mutated lung cancer, a population with high unmet need. The company's progress in securing non-dilutive funding is a positive indicator of its financial stability and ability to advance its programs without diluting shareholder value. Overall, the mid-year update positions Kairos Pharma for continued growth and development in the oncology space.
